ArticleJMIR diabetes2025
DigiBete, a Novel Chatbot to Support Transition to Adult Care of Young People/Young Adults With Type 1 Diabetes Mellitus: Outcomes From a Prospective, Multimethod, Nonrandomized Feasibility and Acceptability Study.
Article in JMIR diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Usability and User Experience Assessment of Health Care Conversational Agents Using Validated Subjective Instruments: Systematic Review and Comparative Analysis.JMIR human factors · 2026Pooled it
- "It's the biggest not one-size-fits-all service I've ever worked in": the realities of delivering a 'Complications of Excess Weight' service for children and young people in England from a multidisciplinary team perspective.BMC health services research · 2026Article
- Artificial Intelligence and Machine Learning in Pediatric Endocrine Tumors: Opportunities, Pitfalls, and a Roadmap for Trustworthy Clinical Translation.Biomedicines · 2026Review
- Reimagining paediatric care: technology, trust, and the global movement for child-centred innovation.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transition to adult health care for young people and young adults (YP/YA) with type 1 diabetes mellitus (T1DM) starts around 11 years of age, but transition services may not meet their needs. A combination of self-management support digital health technologies exists, but no supportive chatbots with components to help YP/YA with T1DM were identified. Objective: The aims of this study were to (1) evaluate the novel DigiBete Chatbot, the first user-led, developmentally appropriate, clinically approved transition chatbot for YP/YA with T1DM from four English diabetes services and (2) assess the feasibility of a future trial of the chatbot. Methods: In a prospective, multimethod, nonrandomized feasibility and acceptability study in the UK National Health Service, YP/YA with T1DM from 4 hospital diabetes clinics (2 pretransition and 2 posttransition) were enrolled in a 6-week study to test the DigiBete Chatbot. During the study, YP/YA completed web-based, validated, and standardized questionnaires at baseline, 2 weeks, and 6 weeks to evaluate quality of life and anxiety and depression, along with chatbot usability and acceptability. Qualitative interviews involving YP/YA, parents, and health care professionals explored their views on the chatbot. Data were analyzed using descriptive statistics and framework analysis. Results: Eighteen YP/YA were enrolled. Qualitative interviews were conducted with 4 parents, 24 health care professionals, and 12 YP/YA. Questionnaire outputs and the emergent qualitative themes (living with T1DM, using the chatbot, and refining the chatbot) indicated that the measures are feasible to use and the chatbot is acceptable and functional. In addition, responses indicated that, with refinements that incorporate the feasibility results, the chatbot could beneficially support YP/YA during transition. Users scored the chatbot as "good" to "excellent" for being engaging, informative, and aesthetically pleasing, and they stated that they would use it again. The results suggest that, with some adaptations based on user feedback, the chatbot was feasible and acceptable among the YP/YA who enjoyed using it. Our reactive conversational agent offers content (messaging and additional multimedia resources) that is relevant for the target population and clinically approved. The DigiBete Chatbot addresses the identified lack of personalized and supported self-management tools available for 11-24 year olds with T1DM and other chronic conditions. Conclusions: These results warrant chatbot refinement and further investigation in a full trial to augment it prior to its wider clinical use. Our research design and methodology could also be transferred to using chatbots for other long-term conditions. On the premise of this feasibility study, the plan is to rebuild the DigiBete Chatbot to meet identified user needs and preferences and progress to a national cohort study to assess the usability, feasibility, and acceptability of a modified chatbot, with a view to proceeding to rollout for national and international use on the established DigiBete platform.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.